1. Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma in Patients with Cirrhosis: Evaluation of Damage to Nontumorous Liver Tissue—Long-term Prospective Study
- Author
-
Michele Nardella, Eugenio Caturelli, Saverio Fusilli, Balzano S, Florio F, Domenico Angelo Siena, Giuseppe Schiavone, and Maria Rosaria Villani
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cirrhosis ,medicine.medical_treatment ,Contrast Media ,Gastroenterology ,Hemostatics ,Hepatic Artery ,Internal medicine ,Catheterization, Peripheral ,Carcinoma ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Longitudinal Studies ,Prospective Studies ,Embolization ,Chemoembolization, Therapeutic ,Prospective cohort study ,Transcatheter arterial chemoembolization ,Aged ,Aged, 80 and over ,Chemotherapy ,Antibiotics, Antineoplastic ,business.industry ,Liver Neoplasms ,Remission Induction ,Age Factors ,Iodized Oil ,Middle Aged ,medicine.disease ,Gelatin Sponge, Absorbable ,digestive system diseases ,Iopamidol ,Surgery ,Liver ,Doxorubicin ,Hepatocellular carcinoma ,Retreatment ,Female ,Liver function ,business ,Follow-Up Studies - Abstract
To evaluate damage to cirrhotic liver tissue after transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).TACE was performed in 111 patients with HCC that involved less than 30% of the liver. Baseline liver function was evaluated with Child-Pugh scores and other indicators. Eighty-two patients had Child-Pugh class A disease, 27 had class B disease, and two had class C disease. All patients underwent chemotherapy followed by gelatin sponge particle embolization in the proper ("complete" embolization; n = 69) or right or left main ("partial" embolization; n = 42) hepatic artery. Liver function was assessed 4 months later, and 95 patients underwent a second TACE (complete embolization in 57, partial in 38). Liver function was again assessed 4 months later in 60 patients.No patient died. Child-Pugh scores increased in all patients from a mean 5.96 to 6.28 (not significant) and 6.51 (P =. 05) after first and second TACEs, respectively. In patients with class A disease, scores increased from a mean 5.37 to 5.73 (P =.01) and 5.89 (P =.001) after first and second TACEs, respectively; in patients with class B disease, scores changed from a mean of 7.48 to 7.67 and 7.30 after first and second TACEs, respectively (not significant).TACE does not induce significant long-term worsening of liver function in patients with class A or B cirrhosis.
- Published
- 2000